A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity

Statistical Methods in Medical Research

Volumn 25, Issue 2, 2016, Pages 659-673

  Braun, Thomas M ^a   Kang, Shan ^a   Taylor, Jeremy M G ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adaptive design; Dose finding studies; early phase clinical trials; most successful dose

Indexed keywords

ADVERSE DRUG REACTION; ALGORITHM; DOSE RESPONSE; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROBABILITY; REVIEW; SIMULATION; STATISTICAL MODEL; BAYES THEOREM; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZATION;

ALGORITHMS; BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; RANDOM ALLOCATION;

EID: 84964282505     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280212464541     Document Type: Review

References (23)

1. Thall PF, Russell KT,. A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998; 54: 251-264
2. Braun TM,. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Control Clin Trial 2002; 23: 240-256
3. Ivanova A,. A new dose-finding design for bivariate outcomes. Biometrics 2003; 59: 1001-1007
4. Thall PF, Cook JD,. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684-693
5. Yin G, Li Y, Ji Y,. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 2006; 62: 777-787
6. O'Quigley J, Hughes MD, Fenton T,. Dose-finding designs for HIV studies. Biometrics 2001; 57: 1018-1029
7. O'Quigley J, Pepe M, Fisher L,. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48
8. Zohar S, O'Quigley J,. Identifying the most successful dose (MSD) in dose-finding studies in cancer. Pharmaceut Stat 2006; 5: 187-199
9. Zohar S, O'Quigley J,. Optimal designs for estimating the most successful dose. Stat Med 2006; 25: 4311-4320
10. Li Z, Durham SD, Flournoy N,. An adaptive design for maximization of a contingent binary response. IMS Lecture Notes-Monograph Series 1995; 25: 179-196
11. Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132: 99-104
12. Lee SM, Cheung YK,. Calibration of prior variance in the Bayesian continual reassessment method. Stat Med 2011; 30: 2081-2089
13. Thall P, Inoue LYT, Martin TG,. Adaptive decision making in a lymphocyte infusion trial. Biometrics 2002; 58: 560-568
14. O'Quigley J, Reiner E,. A stopping rule for the continual reassessment method. Biometrika 1998; 85: 741-748
15. Rosenberger WF, Stallard N, Ivanova A, et al. Optimal adaptive designs for binary response trials. Biometrics 2001; 57: 909-913
16. Braun TM, Yuan Z, Thall PF, et al. Determining a maximum tolerated schedule of a cytotoxic agent. Biometrics 2005; 61: 335-343
17. Liu C, Braun TM,. Parametric non-mixture cure models for schedule finding of therapeutic agents. J Roy Stat Soc Ser C 2009; 58: 225-236
18. Whitehead J, Brunier H,. Bayesian decision procedures for dose determining experiments. Stat Med 1995; 14: 885-893
19. Le Tourneau C, Lee JJ, Siu LL,. Dose escalation methods in phase I cancer clinical trials. J Nat Cancer Inst 2009; 101: 708-720
20. Azriel D, Mandel M, Rinott Y,. The treatment versus experimentation dilemma in dose finding studies. J Stat Plan Infer 2011; 141: 2759-2768
21. Magnussen S,. An algorithm for generating positively correlated beta-distributed random variables with known marginal distributions and a specified correlation. Comput Stat Data Anal 2004; 46: 397-406
22. Cheung YK, Chappell R,. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56: 1177-1182
23. Yuan Y, Yin G,. Robust EM continual reassessment method in oncology dose finding. J Am Stat Assoc 2011; 106: 818-831